Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 3/2004

01-03-2004 | Article

Antibiotic Resistance Rates and Phenotypes Among Isolates of Enterobacteriaceae in French Extra-Hospital Practice

Authors: C. Quentin, C. Arpin, V. Dubois, C. André, I. Lagrange, I. Fischer, J.-P. Brochet, F. Grobost, J. Jullin, B. Dutilh, G. Larribet, P. Noury

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 3/2004

Login to get access

Abstract

Antibiotic resistance among members of the family Enterobacteriaceae was prospectively surveyed by eight French private laboratories over a 5-month period in 1999. A total of 2,599 consecutive and nonduplicate strains were collected, mainly (60.9%) from patients in the community. Most strains (82.9%) derived from urine. Escherichia coli was the predominant (73.9%) organism isolated. The overall rates of antibiotic resistance were as follows: amoxicillin, 53.4%; amoxicillin-clavulanic acid, 27.3%; ticarcillin, 44.2%; piperacillin-tazobactam, 3.2%; cephalothin, 29.2%; cefuroxime, 14.7%; cefoxitin, 11.5%; ceftazidime, 3.6%; cefotaxime, 2.8%; cefepime, 0.3%; imipenem, 0.1%; gentamicin (G), 3.8%; tobramycin (T), 5.0%; netilmicin (Nt), 3.7%; amikacin (A), 0.7%; nalidixic acid, 14.3%; ofloxacin, 10.4%; cotrimoxazole, 21.1%; nitrofurantoin, 12.7%; fosfomycin, 5.2%; tetracycline, 50.1%; and colistin, 12.5%. Beta-lactam resistance phenotypes essentially comprised penicillinase production (33.9%), overexpression of chromosomal cephalosporinase (4.6%), and synthesis of inhibitor-resistant TEM/OXA enzymes (1.5%) or extended-spectrum β-lactamases (1.5%). Aminoglycoside resistance phenotypes consisted of GTNt (93 strains), TNtA (68 strains), GTNtA (14 strains), T (4 strains), GT (3 strains), G (1 strain), and reduced uptake/permeability (3 strains). Most of the nalidixic acid-resistant strains were resistant to ofloxacin (72.8%). Antibiotic resistance rates and phenotypes varied widely according to the bacterial group and the source of the strains. Significantly higher rates were observed in private healthcare centers than in the community, due to a higher proportion of both resistant species and resistant strains. However, multidrug-resistant isolates, including five extended-spectrum β-lactamase-producing strains, were also recovered from the community.
Literature
1.
go back to reference Péan Y, Goldstein FW, Guerrier ML, De Bels F, les membres de VIGIL’ROC (1999) Sensibilité aux β-lactamines des bactéries isolées en ville et à l’hôpital au cours d’une enquête multicentrique française. Antibiotiques 1:165–170 Péan Y, Goldstein FW, Guerrier ML, De Bels F, les membres de VIGIL’ROC (1999) Sensibilité aux β-lactamines des bactéries isolées en ville et à l’hôpital au cours d’une enquête multicentrique française. Antibiotiques 1:165–170
2.
go back to reference Robert J, Cambau E, Grenet K, Trystram D, Péan Y, Fiévet MH, Jarlier V (2001) Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98. Clin Microbiol Infect 7:553–561CrossRefPubMed Robert J, Cambau E, Grenet K, Trystram D, Péan Y, Fiévet MH, Jarlier V (2001) Trends in quinolone susceptibility of Enterobacteriaceae among inpatients of a large university hospital: 1992–98. Clin Microbiol Infect 7:553–561CrossRefPubMed
3.
go back to reference Sirot J, Nicolas-Chanoine MH, Chardon H, Avril JL, Cattoen C, Croix JC, Dabernat H, Fosse T, Ghnassia JC, Lecaillon E, Marmonier A, Roussel-Delvallez M, Soussy CJ, Trevoux A, Vandenesch F, Dib C, Moniot-Ville N, Rezvani Y (2002) Susceptibility of Enterobacteriaceae to β-lactam agents and fluoroquinolones: a 3-year survey in France. Clin Microbiol Infect 8:207–213CrossRefPubMed Sirot J, Nicolas-Chanoine MH, Chardon H, Avril JL, Cattoen C, Croix JC, Dabernat H, Fosse T, Ghnassia JC, Lecaillon E, Marmonier A, Roussel-Delvallez M, Soussy CJ, Trevoux A, Vandenesch F, Dib C, Moniot-Ville N, Rezvani Y (2002) Susceptibility of Enterobacteriaceae to β-lactam agents and fluoroquinolones: a 3-year survey in France. Clin Microbiol Infect 8:207–213CrossRefPubMed
4.
go back to reference Arzouni JP, Bouilloux JP, De Moüy D, Fleutiaux S, Galinier J, Gayon A, Lacharme H, Larribet G, Lepargneur JP (2000) Les infections urinaires chez la femme de 15 à 65 ans en pratique de ville: surveillance de la sensibilité de Escherichia coli à la fosfomycine trométanol en fonction des antécédents. Méd Mal Infect 30:699–702 Arzouni JP, Bouilloux JP, De Moüy D, Fleutiaux S, Galinier J, Gayon A, Lacharme H, Larribet G, Lepargneur JP (2000) Les infections urinaires chez la femme de 15 à 65 ans en pratique de ville: surveillance de la sensibilité de Escherichia coli à la fosfomycine trométanol en fonction des antécédents. Méd Mal Infect 30:699–702
5.
go back to reference De Moüy D, Berges JL, Bouilloux JP, Charbit N, Fischer I, Grobost F, Larribet G, Porcher T (1997) Sensibilité à la fosfomycine des principales bactéries issues d’infections urinaires observées en pratique de ville chez les femmes de 15 à 65 ans. Méd Mal Infect 27:903–906 De Moüy D, Berges JL, Bouilloux JP, Charbit N, Fischer I, Grobost F, Larribet G, Porcher T (1997) Sensibilité à la fosfomycine des principales bactéries issues d’infections urinaires observées en pratique de ville chez les femmes de 15 à 65 ans. Méd Mal Infect 27:903–906
6.
go back to reference De Moüy D, Cavallo JD, Armengaud A, et des membres de l’Aforcopi-Bio (1998) Escherichia coli et infections urinaires en pratique de ville: étude en fonction des antécédents d’hospitalisation et de traitement antibiotique. BEH 24:105 De Moüy D, Cavallo JD, Armengaud A, et des membres de l’Aforcopi-Bio (1998) Escherichia coli et infections urinaires en pratique de ville: étude en fonction des antécédents d’hospitalisation et de traitement antibiotique. BEH 24:105
7.
go back to reference De Moüy D, Cavallo JD, Armengaud M, Arzouni JP, Berges JL, Bouilloux JP, Charbit N, Cirioni N, Fabre R, Garrabe E, Galinier J, Gayon A, Grobost F, Larribet G, Lepargneur JP (1999) Infections urinaires en pratique de ville: étiologies et sensibilité aux antibiotiques en fonction des antécédents. Presse Med 28:1624–1628PubMed De Moüy D, Cavallo JD, Armengaud M, Arzouni JP, Berges JL, Bouilloux JP, Charbit N, Cirioni N, Fabre R, Garrabe E, Galinier J, Gayon A, Grobost F, Larribet G, Lepargneur JP (1999) Infections urinaires en pratique de ville: étiologies et sensibilité aux antibiotiques en fonction des antécédents. Presse Med 28:1624–1628PubMed
8.
go back to reference De Moüy D, Cavallo JD, Fabre R, Garrabe E, Grobost F, Armengaud M, Labia R, et les membres de l’Aforcopibio (1997) Les entérobactéries isolées d’infections urinaires en pratique de ville: étude AFORCOPIBIO. Méd Mal Infect 27:642–645 De Moüy D, Cavallo JD, Fabre R, Garrabe E, Grobost F, Armengaud M, Labia R, et les membres de l’Aforcopibio (1997) Les entérobactéries isolées d’infections urinaires en pratique de ville: étude AFORCOPIBIO. Méd Mal Infect 27:642–645
9.
go back to reference Goldstein FW, and the Multicentre Study Group (2000) Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 19:112–117CrossRefPubMed Goldstein FW, and the Multicentre Study Group (2000) Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections in France. Eur J Clin Microbiol Infect Dis 19:112–117CrossRefPubMed
10.
go back to reference Observatoire National de l’Epidémiologie de la Résistance des Bactéries aux Antibiotiques (ONERBA) (2000) Facteurs influant sur la fréquence et sur le niveau de sensibilité aux antibiotiques des souches d’Escherichia coli et Proteus mirabilis isolées au cours des infections urinaires chez les patients ambulatoires. Méd Mal Infect 30:714–720 Observatoire National de l’Epidémiologie de la Résistance des Bactéries aux Antibiotiques (ONERBA) (2000) Facteurs influant sur la fréquence et sur le niveau de sensibilité aux antibiotiques des souches d’Escherichia coli et Proteus mirabilis isolées au cours des infections urinaires chez les patients ambulatoires. Méd Mal Infect 30:714–720
11.
go back to reference Bradley SF (1999) Issues in the management of resistant bacteria in long-term-care facilities. Infect Control Hosp Epidemiol 20:362–366PubMed Bradley SF (1999) Issues in the management of resistant bacteria in long-term-care facilities. Infect Control Hosp Epidemiol 20:362–366PubMed
12.
go back to reference Nicolle LE, Strausbaugh LJ, Garibaldi RA (1996) Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 9:1–17PubMed Nicolle LE, Strausbaugh LJ, Garibaldi RA (1996) Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 9:1–17PubMed
13.
go back to reference Vromen M, Van der Ven AJAM, Knols A, Stobberingh EE (1999) Antimicrobial resistance patterns in urinary isolates from nursing home residents. Fifteen years of data reviewed. J Antimicrob Chemother 44:113–116CrossRefPubMed Vromen M, Van der Ven AJAM, Knols A, Stobberingh EE (1999) Antimicrobial resistance patterns in urinary isolates from nursing home residents. Fifteen years of data reviewed. J Antimicrob Chemother 44:113–116CrossRefPubMed
14.
go back to reference Courvalin P (1992) Interpretive reading of antimicrobial susceptibility tests. ASM News 58:368–375 Courvalin P (1992) Interpretive reading of antimicrobial susceptibility tests. ASM News 58:368–375
15.
go back to reference Livermore DM (1995) β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584PubMed Livermore DM (1995) β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 8:557–584PubMed
16.
go back to reference Livermore DM, Winstanley TG, Shannon KP (2001) Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 48 (Suppl S1):87–102 Livermore DM, Winstanley TG, Shannon KP (2001) Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 48 (Suppl S1):87–102
17.
go back to reference De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J, and the French Study Group (2000) A 1998 survey of extended-spectrum β-lactamases in Enterobacteriaceae in France. Antimicrob Agents Chemother 44:3177–3179CrossRefPubMed De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J, and the French Study Group (2000) A 1998 survey of extended-spectrum β-lactamases in Enterobacteriaceae in France. Antimicrob Agents Chemother 44:3177–3179CrossRefPubMed
18.
go back to reference Henquell C, Sirot D, Chanal C, De Champs C, Chatron P, Lafeuille B, Texier P, Sirot J, Cluzel R (1994) Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother 34:707–714PubMed Henquell C, Sirot D, Chanal C, De Champs C, Chatron P, Lafeuille B, Texier P, Sirot J, Cluzel R (1994) Frequency of inhibitor-resistant TEM β-lactamases in Escherichia coli isolates from urinary tract infections in France. J Antimicrob Chemother 34:707–714PubMed
19.
go back to reference Jarlier V, Nordmann P (2000) Entérobactéries et β-lactamines. In: Freney J, Renaud F, Hansen W, Bollet C (eds) Précis de bactériologie clinique. ESKA, Paris, pp 649–665 Jarlier V, Nordmann P (2000) Entérobactéries et β-lactamines. In: Freney J, Renaud F, Hansen W, Bollet C (eds) Précis de bactériologie clinique. ESKA, Paris, pp 649–665
20.
go back to reference Leflon-Guibout V, Speldooren V, Heym B, Nicolas-Chanoine MH (2000) Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla TEM genes. Antimicrob Agents Chemother 44:2709–2714CrossRefPubMed Leflon-Guibout V, Speldooren V, Heym B, Nicolas-Chanoine MH (2000) Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla TEM genes. Antimicrob Agents Chemother 44:2709–2714CrossRefPubMed
21.
go back to reference Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA (1999) Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:517–523CrossRefPubMed Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA (1999) Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 281:517–523CrossRefPubMed
22.
go back to reference Cormican M, Morris D, Corbett-Feeeney G, Flynn J (1998) Extended spectrum β-lactamase production and fluoroquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis 32:317–319CrossRefPubMed Cormican M, Morris D, Corbett-Feeeney G, Flynn J (1998) Extended spectrum β-lactamase production and fluoroquinolone resistance in pathogens associated with community acquired urinary tract infection. Diagn Microbiol Infect Dis 32:317–319CrossRefPubMed
23.
go back to reference Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W (2001) Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 47:773–780CrossRefPubMed Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W (2001) Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 47:773–780CrossRefPubMed
25.
go back to reference Lambert T, Courvalin P (2000) Entérobactéries et aminosides. In: Freney J, Renaud F, Hansen W, Bollet C (eds) Précis de bactériologie clinique. ESKA, Paris, pp 666–677 Lambert T, Courvalin P (2000) Entérobactéries et aminosides. In: Freney J, Renaud F, Hansen W, Bollet C (eds) Précis de bactériologie clinique. ESKA, Paris, pp 666–677
26.
go back to reference Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ, and the Aminoglycoside Resistance Study Groups (1997) The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin Infect Dis 24 (Suppl 1):46–62 Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, Shlaes D, Shimizu K, Shaw KJ, and the Aminoglycoside Resistance Study Groups (1997) The most frequent aminoglycoside resistance mechanisms—changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin Infect Dis 24 (Suppl 1):46–62
27.
go back to reference Jones RN (1998) Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 31:461–466CrossRefPubMed Jones RN (1998) Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: the Amp C enzymes. Diagn Microbiol Infect Dis 31:461–466CrossRefPubMed
28.
go back to reference Sanders WE, Sanders CC (1997) Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 10:220–241PubMed Sanders WE, Sanders CC (1997) Enterobacter spp.: pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 10:220–241PubMed
29.
go back to reference Gheorghiu R, Yuan M, Hall LMC, Livermore DM (1997) Bases of variation in resistance to β-lactams in Klebsiella oxytoca isolates hyperproducing K1 β-lactamase. J Antimicrob Chemother 40:533–541CrossRefPubMed Gheorghiu R, Yuan M, Hall LMC, Livermore DM (1997) Bases of variation in resistance to β-lactams in Klebsiella oxytoca isolates hyperproducing K1 β-lactamase. J Antimicrob Chemother 40:533–541CrossRefPubMed
30.
go back to reference Chaïbi EB, Sirot D, Paul G, Labia R (1999) Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 43:447–458CrossRefPubMed Chaïbi EB, Sirot D, Paul G, Labia R (1999) Inhibitor-resistant TEM β-lactamases: phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 43:447–458CrossRefPubMed
31.
go back to reference Arpin C, Labia R, Dubois V, Noury P, Souquet M, Quentin C (2002) TEM-80, a novel inhibitor-resistant β-lactamase in a clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother 46:1183–1189CrossRefPubMed Arpin C, Labia R, Dubois V, Noury P, Souquet M, Quentin C (2002) TEM-80, a novel inhibitor-resistant β-lactamase in a clinical isolate of Enterobacter cloacae. Antimicrob Agents Chemother 46:1183–1189CrossRefPubMed
32.
go back to reference Nordmann P (1998) Trends in β-lactam resistance among Enterobacteriaceae. Clin Infect Dis 27 (Suppl 1):100–106PubMed Nordmann P (1998) Trends in β-lactam resistance among Enterobacteriaceae. Clin Infect Dis 27 (Suppl 1):100–106PubMed
33.
go back to reference Bermudes H, Arpin C, Jude F, El-Harrif Z, Bébéar C, Quentin C (1997) Molecular epidemiology of an outbreak due to extended-spectrum β-lactamase-producing enterobacteria in a French hospital. Eur J Clin Microbiol Infect Dis 16:523–529PubMed Bermudes H, Arpin C, Jude F, El-Harrif Z, Bébéar C, Quentin C (1997) Molecular epidemiology of an outbreak due to extended-spectrum β-lactamase-producing enterobacteria in a French hospital. Eur J Clin Microbiol Infect Dis 16:523–529PubMed
34.
go back to reference Gniadkowski M (2001) Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 7:597–608CrossRefPubMed Gniadkowski M (2001) Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 7:597–608CrossRefPubMed
35.
go back to reference Arpin C, Coze C, Rogues AM, Gachie JP, Bébéar C, Quentin C (1996) Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in a medical intensive care unit. J Clin Microbiol 34:2163–2169PubMed Arpin C, Coze C, Rogues AM, Gachie JP, Bébéar C, Quentin C (1996) Epidemiological study of an outbreak due to multidrug-resistant Enterobacter aerogenes in a medical intensive care unit. J Clin Microbiol 34:2163–2169PubMed
36.
go back to reference Bosi C, Davin-Regli A, Bornet C, Mallea M, Pages JM, Bollet C (1999) Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol 37:2165–2169PubMed Bosi C, Davin-Regli A, Bornet C, Mallea M, Pages JM, Bollet C (1999) Most Enterobacter aerogenes strains in France belong to a prevalent clone. J Clin Microbiol 37:2165–2169PubMed
37.
go back to reference Hernández-Allés S, Benedí VJ, Martínez-Martínez L, Pascual Á, Aguilar A, Tomás JM, Albertí S (1999) Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob Agents Chemother 43:937–939PubMed Hernández-Allés S, Benedí VJ, Martínez-Martínez L, Pascual Á, Aguilar A, Tomás JM, Albertí S (1999) Development of resistance during antimicrobial therapy caused by insertion sequence interruption of porin genes. Antimicrob Agents Chemother 43:937–939PubMed
38.
go back to reference Arpin C, Dubois V, Coulange L, André C, Fischer I, Noury P, Grobost F, Brochet J-P, Jullin J, Dutilh B, Larribet G, Lagrange I, Quentin C (2003) Extended-spectrum ß-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 47:3506–3514CrossRefPubMed Arpin C, Dubois V, Coulange L, André C, Fischer I, Noury P, Grobost F, Brochet J-P, Jullin J, Dutilh B, Larribet G, Lagrange I, Quentin C (2003) Extended-spectrum ß-lactamase-producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 47:3506–3514CrossRefPubMed
39.
go back to reference Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C (2000) Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 38:1048–1052PubMed Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C (2000) Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 38:1048–1052PubMed
40.
go back to reference Acar JF, Goldstein FW (1997) Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24 (Suppl 1):67–73 Acar JF, Goldstein FW (1997) Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24 (Suppl 1):67–73
41.
go back to reference Bird J, Browning R, Hobson RP, MacKenzie FM, Brand J, Gould IM (1998) Multiply-resistant Klebsiella pneumoniae: failure of spread in community-based elderly care facilities. J Hosp Infect 40:243–247PubMed Bird J, Browning R, Hobson RP, MacKenzie FM, Brand J, Gould IM (1998) Multiply-resistant Klebsiella pneumoniae: failure of spread in community-based elderly care facilities. J Hosp Infect 40:243–247PubMed
42.
go back to reference Rice LB, Eckstein EC, DeVente J, Shlaes DM (1996) Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs medical center. Clin Infect Dis 23:118–124PubMed Rice LB, Eckstein EC, DeVente J, Shlaes DM (1996) Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs medical center. Clin Infect Dis 23:118–124PubMed
43.
go back to reference Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC, Jacoby GA (1990) Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 34:2193–2199PubMed Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC, Jacoby GA (1990) Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 34:2193–2199PubMed
44.
go back to reference Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, Rahal JJ, Bush K (1995) SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 39:899–905PubMed Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, Rahal JJ, Bush K (1995) SHV-7, a novel cefotaxime-hydrolyzing β-lactamase, identified in Escherichia coli isolates from hospitalized nursing home patients. Antimicrob Agents Chemother 39:899–905PubMed
45.
go back to reference Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K (1993) Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 β-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother 37:1989–1992PubMed Rasmussen BA, Bradford PA, Quinn JP, Wiener J, Weinstein RA, Bush K (1993) Genetically diverse ceftazidime-resistant isolates from a single center: biochemical and genetic characterization of TEM-10 β-lactamases encoded by different nucleotide sequences. Antimicrob Agents Chemother 37:1989–1992PubMed
46.
go back to reference Heseltine P (2000) Has resistance spread to the community? Clin Microbiol Infect 6 (Suppl 2):11–16CrossRefPubMed Heseltine P (2000) Has resistance spread to the community? Clin Microbiol Infect 6 (Suppl 2):11–16CrossRefPubMed
47.
go back to reference Gupta K, Hooton TM, Stamm WE (2001) Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135:41–50PubMed Gupta K, Hooton TM, Stamm WE (2001) Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135:41–50PubMed
Metadata
Title
Antibiotic Resistance Rates and Phenotypes Among Isolates of Enterobacteriaceae in French Extra-Hospital Practice
Authors
C. Quentin
C. Arpin
V. Dubois
C. André
I. Lagrange
I. Fischer
J.-P. Brochet
F. Grobost
J. Jullin
B. Dutilh
G. Larribet
P. Noury
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 3/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-003-1081-5

Other articles of this Issue 3/2004

European Journal of Clinical Microbiology & Infectious Diseases 3/2004 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.